Helen Torley
PRESIDENT AND CEO at Halozyme Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Halozyme Therapeutics Inc. May 1, 202599.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 8, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 8, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −4,810 | $108.18 | $520,341 |
| Oct 8, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −3,090 | $108.91 | $336,526 |
| Oct 8, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −11,900 | $110.00 | $1,308,941 |
| Oct 8, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −200 | $110.51 | $22,102 |
| Oct 7, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 7, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −8,600 | $111.03 | $954,867 |
| Oct 7, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −10,300 | $111.84 | $1,151,942 |
| Oct 7, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −900 | $112.78 | $101,502 |
| Oct 7, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −200 | $113.69 | $22,739 |
| Oct 6, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Oct 6, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −2,300 | $107.90 | $248,175 |
| Oct 6, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −6,000 | $109.33 | $656,004 |
| Oct 6, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −9,920 | $109.89 | $1,090,119 |
| Oct 6, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −1,780 | $110.81 | $197,245 |
Questions about Helen Torley
What boards is Helen Torley on?
Helen Torley sits on the board of Halozyme Therapeutics Inc.
What company is Helen Torley the CEO of?
Helen Torley is PRESIDENT AND CEO of Halozyme Therapeutics Inc.
How long has Helen Torley served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.